<?xml version='1.0' encoding='utf-8'?>
<document id="22627182"><sentence text="Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers."><entity charOffset="24-33" id="DDI-PubMed.22627182.s1.e0" text="lopinavir" /><entity charOffset="34-43" id="DDI-PubMed.22627182.s1.e1" text="ritonavir" /><entity charOffset="71-83" id="DDI-PubMed.22627182.s1.e2" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.22627182.s1.e0" e2="DDI-PubMed.22627182.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22627182.s1.e0" e2="DDI-PubMed.22627182.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s1.e0" e2="DDI-PubMed.22627182.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22627182.s1.e1" e2="DDI-PubMed.22627182.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s1.e1" e2="DDI-PubMed.22627182.s1.e2" /></sentence><sentence text="Pitavastatin, a statin recently approved in the United States, has a potential benefit of reduced risk of cytochrome P450 (CYP)-mediated drug-drug interaction due to minimal metabolism by the CYP system"><entity charOffset="0-12" id="DDI-PubMed.22627182.s2.e0" text="Pitavastatin" /></sentence><sentence text=" The primary objective was to investigate pharmacokinetic (PK) effects of lopinavir/ritonavir 400 mg/100 mg twice daily on pitavastatin 4 mg when coadministered"><entity charOffset="74-83" id="DDI-PubMed.22627182.s3.e0" text="lopinavir" /><entity charOffset="84-93" id="DDI-PubMed.22627182.s3.e1" text="ritonavir" /><entity charOffset="123-135" id="DDI-PubMed.22627182.s3.e2" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.22627182.s3.e0" e2="DDI-PubMed.22627182.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22627182.s3.e0" e2="DDI-PubMed.22627182.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s3.e0" e2="DDI-PubMed.22627182.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22627182.s3.e1" e2="DDI-PubMed.22627182.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s3.e1" e2="DDI-PubMed.22627182.s3.e2" /></sentence><sentence text="" /><sentence text="This was an open-label one-arm study" /><sentence text="" /><sentence text="Pitavastatin 4 mg was administered once daily (days 1-5 and days 20-24)"><entity charOffset="0-12" id="DDI-PubMed.22627182.s7.e0" text="Pitavastatin" /></sentence><sentence text=" Lopinavir/ritonavir 400 mg/100 mg was administered twice daily (days 9-24)"><entity charOffset="1-10" id="DDI-PubMed.22627182.s8.e0" text="Lopinavir" /><entity charOffset="11-20" id="DDI-PubMed.22627182.s8.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22627182.s8.e0" e2="DDI-PubMed.22627182.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22627182.s8.e0" e2="DDI-PubMed.22627182.s8.e1" /></sentence><sentence text=" Plasma samples for PK assessments were collected on days 5, 19, and 24" /><sentence text=" Plasma concentrations of analytes were determined by liquid chromatography with tandem mass spectrometric detection methods" /><sentence text="" /><sentence text="PK data were available for 23 of 24 subjects enrolled" /><sentence text=" For pitavastatin, area under the concentration time curve (AUC0-τ) and maximum concentration (C(max)) were 136"><entity charOffset="5-17" id="DDI-PubMed.22627182.s13.e0" text="pitavastatin" /></sentence><sentence text="8 ± 52" /><sentence text="9 ng·h(-1)·mL(-1) and 58" /><sentence text="6 ± 30" /><sentence text="4 ng/mL, respectively, when given alone, versus 113" /><sentence text="9 ± 53" /><sentence text="8 ng·h(-1)·mL(-1) and 58" /><sentence text="2 ± 32" /><sentence text="7 ng/mL when combined with lopinavir/ritonavir"><entity charOffset="27-36" id="DDI-PubMed.22627182.s21.e0" text="lopinavir" /><entity charOffset="37-46" id="DDI-PubMed.22627182.s21.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22627182.s21.e0" e2="DDI-PubMed.22627182.s21.e0" /><pair ddi="false" e1="DDI-PubMed.22627182.s21.e0" e2="DDI-PubMed.22627182.s21.e1" /></sentence><sentence text=" The geometric mean ratio for AUC(0-τ) for pitavastatin with lopinavir/ritonavir versus pitavastatin alone was 80"><entity charOffset="43-55" id="DDI-PubMed.22627182.s22.e0" text="pitavastatin" /><entity charOffset="61-70" id="DDI-PubMed.22627182.s22.e1" text="lopinavir" /><entity charOffset="71-80" id="DDI-PubMed.22627182.s22.e2" text="ritonavir" /><entity charOffset="88-100" id="DDI-PubMed.22627182.s22.e3" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.22627182.s22.e0" e2="DDI-PubMed.22627182.s22.e0" /><pair ddi="false" e1="DDI-PubMed.22627182.s22.e0" e2="DDI-PubMed.22627182.s22.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s22.e0" e2="DDI-PubMed.22627182.s22.e2" /><pair ddi="false" e1="DDI-PubMed.22627182.s22.e0" e2="DDI-PubMed.22627182.s22.e3" /><pair ddi="false" e1="DDI-PubMed.22627182.s22.e1" e2="DDI-PubMed.22627182.s22.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s22.e1" e2="DDI-PubMed.22627182.s22.e2" /><pair ddi="false" e1="DDI-PubMed.22627182.s22.e1" e2="DDI-PubMed.22627182.s22.e3" /><pair ddi="false" e1="DDI-PubMed.22627182.s22.e2" e2="DDI-PubMed.22627182.s22.e2" /><pair ddi="false" e1="DDI-PubMed.22627182.s22.e2" e2="DDI-PubMed.22627182.s22.e3" /></sentence><sentence text="0 (90% confidence interval: 73" /><sentence text="4 to 87" /><sentence text="3) and C(max) was 96" /><sentence text="1 (90% confidence interval: 83" /><sentence text="6 to 110" /><sentence text="4)" /><sentence text=" Median T(max) of pitavastatin was approximately 0"><entity charOffset="18-30" id="DDI-PubMed.22627182.s29.e0" text="pitavastatin" /></sentence><sentence text="5 hours for both treatments" /><sentence text=" The PK effect of pitavastatin on lopinavir/ritonavir was minimal"><entity charOffset="18-30" id="DDI-PubMed.22627182.s31.e0" text="pitavastatin" /><entity charOffset="34-43" id="DDI-PubMed.22627182.s31.e1" text="lopinavir" /><entity charOffset="44-53" id="DDI-PubMed.22627182.s31.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22627182.s31.e0" e2="DDI-PubMed.22627182.s31.e0" /><pair ddi="false" e1="DDI-PubMed.22627182.s31.e0" e2="DDI-PubMed.22627182.s31.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s31.e0" e2="DDI-PubMed.22627182.s31.e2" /><pair ddi="false" e1="DDI-PubMed.22627182.s31.e1" e2="DDI-PubMed.22627182.s31.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s31.e1" e2="DDI-PubMed.22627182.s31.e2" /></sentence><sentence text=" No significant safety issues were reported" /><sentence text="" /><sentence text="The effect on exposures when pitavastatin and lopinavir/ritonavir are coadministered was minimal"><entity charOffset="29-41" id="DDI-PubMed.22627182.s34.e0" text="pitavastatin" /><entity charOffset="46-55" id="DDI-PubMed.22627182.s34.e1" text="lopinavir" /><entity charOffset="56-65" id="DDI-PubMed.22627182.s34.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22627182.s34.e0" e2="DDI-PubMed.22627182.s34.e0" /><pair ddi="false" e1="DDI-PubMed.22627182.s34.e0" e2="DDI-PubMed.22627182.s34.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s34.e0" e2="DDI-PubMed.22627182.s34.e2" /><pair ddi="false" e1="DDI-PubMed.22627182.s34.e1" e2="DDI-PubMed.22627182.s34.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s34.e1" e2="DDI-PubMed.22627182.s34.e2" /></sentence><sentence text=" Concomitant use of pitavastatin and lopinavir/ritonavir was safe and well tolerated in healthy adult volunteers"><entity charOffset="20-32" id="DDI-PubMed.22627182.s35.e0" text="pitavastatin" /><entity charOffset="37-46" id="DDI-PubMed.22627182.s35.e1" text="lopinavir" /><entity charOffset="47-56" id="DDI-PubMed.22627182.s35.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22627182.s35.e0" e2="DDI-PubMed.22627182.s35.e0" /><pair ddi="false" e1="DDI-PubMed.22627182.s35.e0" e2="DDI-PubMed.22627182.s35.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s35.e0" e2="DDI-PubMed.22627182.s35.e2" /><pair ddi="false" e1="DDI-PubMed.22627182.s35.e1" e2="DDI-PubMed.22627182.s35.e1" /><pair ddi="false" e1="DDI-PubMed.22627182.s35.e1" e2="DDI-PubMed.22627182.s35.e2" /></sentence><sentence text="" /></document>